Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Stromal architecture directs early dissemination in pancreatic ductal adenocarcinoma
Arja Ray, Mackenzie K. Callaway, Nelson J. Rodríguez-Merced, Alexandra L. Crampton, Marjorie Carlson, Kenneth B. Emme, Ethan A. Ensminger, Alexander A. Kinne, Jonathan H. Schrope, Haley R. Rasmussen, Hong Jiang, David G. DeNardo, David K. Wood, Paolo P. Provenzano
Arja Ray, Mackenzie K. Callaway, Nelson J. Rodríguez-Merced, Alexandra L. Crampton, Marjorie Carlson, Kenneth B. Emme, Ethan A. Ensminger, Alexander A. Kinne, Jonathan H. Schrope, Haley R. Rasmussen, Hong Jiang, David G. DeNardo, David K. Wood, Paolo P. Provenzano
View: Text | PDF
Research Article Cell biology Oncology

Stromal architecture directs early dissemination in pancreatic ductal adenocarcinoma

  • Text
  • PDF
Abstract

Pancreatic ductal adenocarcinoma (PDA) is an extremely metastatic and lethal disease. Here, in both murine and human PDA, we demonstrate that extracellular matrix architecture regulates cell extrusion and subsequent invasion from intact ductal structures through tumor-associated collagen signatures (TACS). This results in early dissemination from histologically premalignant lesions and continual invasion from well-differentiated disease, and it suggests TACS as a biomarker to aid in the pathologic assessment of early disease. Furthermore, we show that pancreatitis results in invasion-conducive architectures, thus priming the stroma prior to malignant disease. Analysis in potentially novel microfluidic-derived microtissues and in vivo demonstrates decreased extrusion and invasion following focal adhesion kinase (FAK) inhibition, consistent with decreased metastasis. Thus, data suggest that targeting FAK or strategies to reengineer and normalize tumor microenvironments may have roles not only in very early disease, but also for limiting continued dissemination from unresectable disease. Likewise, it may be beneficial to employ stroma-targeting strategies to resolve precursor diseases such as pancreatitis in order to remove stromal architectures that increase risk for early dissemination.

Authors

Arja Ray, Mackenzie K. Callaway, Nelson J. Rodríguez-Merced, Alexandra L. Crampton, Marjorie Carlson, Kenneth B. Emme, Ethan A. Ensminger, Alexander A. Kinne, Jonathan H. Schrope, Haley R. Rasmussen, Hong Jiang, David G. DeNardo, David K. Wood, Paolo P. Provenzano

×

Figure 1

Fibrous collagen architectures in PDA.

Options: View larger image (or click on image) Download as PowerPoint
Fibrous collagen architectures in PDA.
(A–D) Combined MPE and SHG imagin...
(A–D) Combined MPE and SHG imaging of patient samples showing tissue architecture by autofluorescence and fibrous collagen by SHG in (A) normal, (B) cancer-adjacent normal, (C) PanIN, and (D) mature PDA (# and ##, 2× magnifications of the indicated regions) and related (E) collagen quantification (n = 10–21 fields of view [FOV] across n ≥ 3 patient samples per group). (F–I) Combined MPE/SHG imaging and analysis using KPCT or KPCG mouse models of PDA for (F) normal, (G) cancer-adjacent normal, (H) PanIN, and (I) well-differentiated PDA and related (J) collagen quantification (n = 5–12 FOV across n ≥ 3 mice per group). (K) Typical collagen architectures in early disease (1.5-month KPCT mouse) (# and ##, 3× magnifications of the indicated regions; outlined and solid arrowhead, TACS-3 and TACS-2, respectively). (L) Frequency of quantified TACS (per duct) associated with PanIN and well-differentiated PDA in KPCT/KPCG mice (n > 20 FOV across ≥ 6 mouse tumors/group; by 2-way ANOVA, P < 0.0001 for TACS type and ns for PanIN/PDA as main effects; ns for association of each of None, TACS-2 only, and TACS-3 with PanIN versus PDA by Tukey’s multiple-comparison test). (M and N) Representative TACS-2+ and TACS-3+ ducts in well-differentiated human PDA, with yellow dashed lines indicating ductal boundaries (M), quantified by CT-FIRE (60) (N). (O) Frequency of TACS-2 and TACS-3 associated with ductal structures from different stages of human disease (n = 10–33 FOV across n ≥ 3 patient samples; P = 0.15 and P = 0.41 by Fisher’s exact test for the association of stage with None versus TACS and TACS-2 only versus TACS-3, respectively). Scale bars: 50 μm (A–D, F–I, and K) and 20 μm (M); box-and-whisker plots show minimum to maximum with median and interquartile range for E and J; *P < 0.05, **P < 0.01, ***P < 0.001 by the nonparametric Kruskal-Wallis test and Dunn’s multiple-comparison test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts